

References

L-34

Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

1. Barahona-Dussault C, Benito B, Campuzano O, et al. Role of genetic testing in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Clin Genet*. 2010 77:37-48.
2. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. *Can J Cardiol*. 2011 Mar-Apr;27(2):232-45.
3. Hendrix A, Borleffs CJ, Vink A, et al. Cardiogenetic screening of first-degree relatives after sudden cardiac death in the young: a population-based approach. *Europace*. 2011 May;13(5):716-22.

BluePrint

1. Etchegary H1, Pullman D, Simmonds C. 'It had to be done': genetic testing decisions for arrhythmogenic right ventricular cardiomyopathy. *Clin Genet*. 2014 Sep 29.

Bone Marrow Failure and Myelodysplastic Syndromes

1. Zhang MY, Keel SB, Walsh T, et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. *Haematologica*. Sep 19 2014.

Brugada

1. Arkadia Konstantopoulou, Spyros Tsirikas, Dimitrios Asvestas, et al. Mechanisms of drug-induced proarrhythmia in clinical practice. *World J Cardiol*. 2013 Jun 26; 5(6): 175–185.
2. Blom MT1, Cohen D, Seldenrijk A, et al. Brugada Syndrome ECG Is Highly Prevalent in Schizophrenia. *Circ Arrhythm Electrophysiol*. 2014 Mar 3.
3. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. *Can J Cardiol*. 2011 Mar-Apr;27(2):232-45.
4. Hofman N, Tan HL, Alders M, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? *J Am Coll Cardiol*. 2010 Jun 8;55(23):2570-6.
5. Hu D, Barajas-Martinez H, Pfeiffer R, et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. *J Am Coll Cardiol*. Jul 8 2014;64(1):66-79.
6. Svendsen JH, Geelen P. Screening for, and management of, possible arrhythmogenic syndromes (channelopathies/ion channel diseases). *Europace*. 2010 12:741-742.

Cadasil

1. Opherck C, Gonik M, Duering M, et al. Genome-wide genotyping demonstrates a polygenic risk score associated with white matter hyperintensity volume in CADASIL. *Stroke*. Apr 2014;45(4):968-972.

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

1. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. *Can J Cardiol*. 2011 Mar-Apr;27(2):232-45.

- Hofman N, Tan HL, Alders M, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? *J AM Coll Cardiol*. 2010 Jun 8;55(23):2570-6.

Comparative Genomic Hybridization

- Miller D, Adam M, Aradhya S, et al. Consensus Statement: Chromosomal Microarray is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies. *Am J Human Genetics*. May 14, 2010;86: 749-764/Manning M, Hudgins L. Arraybased technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *ACMG.Practice Guidelines*. November 2010;12(11):742-745.

Developmental Delay/ Intellectual Disability (DDID), Autism Spectrum Disorder (ASD) and/or, Congenital Anomalies

- Battaglia A1, Doccini V, Bernardini L, et al. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. *Eur J Paediatr Neurol*. 2013 Nov;17(6):589-99.
- Blue Cross Blue Shield Association (BCBSA) TEC Special Report. Chromosomal Microarray for the Genetic Evaluation of Patients with Global Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder. August 2015.
- Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. *Genet Med*. 2011;13(9):770-6.
- Ellison JW1, Ravnan JB, Rosenfeld JA. Clinical utility of chromosomal microarray analysis. *Pediatrics*. 2012 Nov;130(5):e1085-95.
- Kearney HM, Thorland EC, Brown KK, et al. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med*. Jul 2011;13(7):680-685.
- Manning, M, MD, MS, FACMG, Hudgins, MD, FACMG. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. Nov 2010; 12(11): 742–745
- Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. Oct 25 2011;77(17):1629-1635
- Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet*. May 14 2010;86(5):749-764
- Sagoo GS, Mohammed S, Barton G, et al. Cost Effectiveness of Using Array-CGH for Diagnosing Learning Disability. *Appl Health Econ Health Policy*. Apr 19 2015.
- Schaefer GB, Mendelsohn NJ, Professional P, et al. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med*. May 2013;15(5):399-407.

12. South ST, Lee C, Lamb AN, et al. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. *Genet Med*. Nov 2013;15(11):901-909.
13. The American college of obstetricians and gynecologists committee on genetics society for maternal-fetal medicine. The use of chromosomal microarray analysis in prenatal diagnosis. Number 581. Dec 2013.
14. Wapner RJ, MD, Martin CL, Ph.D, Levy B, M.Sc. (Med), et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. *The New England Journal of Medicine*. 6 Dec 2012; 2175-2184.

Diagnosis or Risk Assessment of Alzheimer's Disease

1. Darst BF, Kosciak RL, Hermann BP et al. Heritability of Cognitive Traits Among Siblings with a Parental History of Alzheimer's Disease. *J Alzheimers Dis*. 2015 Feb 3.
2. Jin SC, Benitez BA, Karch CM, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. *Hum Mol Genet*. 2014 Nov 1;23(21):5838-46

Hearing Impairment

1. Hoefsloot LH, Roux AF, Bitner-Glindzicz M; contributors to EMQN DFNB1 best practice meeting. EMQN Best Practice guidelines for diagnostic testing of mutations causing non-syndromic hearing impairment at the DFNB1 locus. *Eur J Hum Genet*. 2013 Nov;21(11):1325-9.

Hypertrophic Cardiomyopathy

1. Das KJ, Ingles J, Bagnall RD, et al. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. *Genet Med*. Oct 10 2013.
2. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. *Can J Cardiol*. 2011 Mar-Apr;27(2):232-45.
3. Hendrix A, Borleffs CJ, Vink A, et al. Cardiogenetic screening of first-degree relatives after sudden cardiac death in the young: a population-based approach. *Europace*. 2011 May;13(5):716-22.
4. Jensen, MK, Havndrup, O, Christiansen, M, Andersen, PS, Diness, B, Axelsson, A, Skovby, F, Kober, L, and Bundgaard, H. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. *Circulation*. 2013;127(1):48-54.
5. Maron BJ, Maron MS, and Semsarian C. Genetics of Hypertrophic Cardiomyopathy After 20 Years. *Journal of the American College of Cardiology*. 2012; 60(8):705-15.

Invitae Genetic Assay

1. American Society Clinical Oncology (ASCO). New Recommendations for Family History Taking in Oncology Setting. 2014. www.asco.org. Accessed 7/7/14.
2. Kurian A, Hare E, Mills M, et al. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. *J Clin Oncol*. 2014 Jul 1;32(19):2001-9.
3. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med* 2013; 15(5):399-407

Long-QT Syndrome

1. BCBSA TEC Assessment. Genetic Testing for Long QT Syndrome: 2008. Accessed September 2015.
2. Costa J, Lopes CM, Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. *Heart Rhythm* 2012; 9(6):892-8.
3. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. *Can J Cardiol*. 2011 Mar-Apr;27(2):232-45.
4. Hendrix A, Borleffs CJ, Vink A, et al. Cardiogenetic screening of first-degree relatives after sudden cardiac death in the young: a population-based approach. *Europace*. 2011 May;13(5):716-22.
5. Hofman N, Tan HL, Alders M, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? *J Am Coll Cardiol*. 2010 Jun 8;55(23):2570-6.
6. Kapa S, Tester DJ, Salisbury BA, et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. *Circulation*. Nov 3 2009;120(18):1752-1760.
7. Kumar S, Peters S, Thompson T, et al. Familial cardiological and targeted genetic evaluation: low yield in sudden unexplained death and high yield in unexplained cardiac arrest syndromes. *Heart Rhythm*. Nov 2013;10(11):1653-1660.
8. Perez MV, Kumarasamy NA, Owens, DK et al. Cost-Effectiveness of Genetic Testing in Family Members of Patients With Long-QT Syndrome. 2010 www.ahajournals.org. Accessed September 20, 2015.
9. Schaefer G.B, MD, Mendelsohn NJ, MD. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med*. 2013 May;15(5):399-407.
10. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. *Circulation*. Aug 1993;88(2):782-784.
11. Svendsen JH, Geelen P. Screening for, and management of, possible arrhythmogenic syndromes (channelopathies/ion channel diseases). *Europace*. 2010 12:741-742.
12. Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. *J Am Coll Cardiol*. Feb 21 2006;47(4):764-768.

Marfan Syndrome

1. Groth KA, Gaustadnes M, Thorsen K, et al. Difficulties in diagnosing Marfan syndrome using current FBN1 databases. *Genet Med*. 2015 Mar 26.

Miscellaneous

1. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. *Genet Med*. Mar 2013;15(3):178-186.
2. Agwa E, Ma PC. Overview of various techniques/platforms with critical evaluation of each. *Curr Treat Options Oncol*. 2013 Dec;14(4):623-33.

Mutations Associated with Malignant Melanoma Susceptibility

1. Cutaneous Phenotype and MC1R Variants as Modifying Factors for the Development of Melanoma in CDKN2A G101W Mutation Carriers From 4 Countries, *Int J Cancer*, Volume 121, No. 4, 08/2007
2. Aspinwall LG, Stump TK, Taber JM et al. Impact of melanoma genetic test reporting on perceived control over melanoma prevention. *J Behav Med*. 2015 Mar 31.

Newborn Child Testing

1. The General Assembly of Pennsylvania House Bill 1654. Act 148 Newborn child testing act. Amended 10/15/2014. Effective 12/15/2014.
2. US National Library of Medicine, National Institutes of Health, Department of Health & Human Services. Newborn Screening Coding and Terminology Guide. Available at www.newbornscreeningcodes.nlm.nih.gov. Accessed October 1, 2015.

Prenatal and Preconception Individuals of Ashkenazi Jewish Ancestry

1. Anderson H. Alzheimer Disease. May 6, 2010.
2. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. *Genet Med*. Jun 2013;15(6):482-483.
3. Update on Carrier Screening for Cystic Fibrosis. Committee Opinion. American College of Obstetricians and Gynecologist. 2011 April; 486.

ProMark Prostate Cancer Genetic Test

1. Blume-Jensen P, Berman DM, Rimm DL et al. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Accessed August 1, 2015 www.acr.
2. Shipitsin M, Small C, Giladi E, et al. Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. *Proteome Sci*. 2014;12:40.
3. Shipitsin M, Small C, Giladi E, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. *British Journal of Cancer*. 2014 (111) 1201-1212.

Prostate Cancer

1. Ren S, Xu J, Zhou T et al. Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. *Prostate* 2013; 73(16):1824-35.
2. Tsuchiya N, Matsui S, Narita S et al. Distinct cancer-specific survival in metastatic prostate cancer patients classified by a panel of single nucleotide polymorphisms of cancer-associated genes. *Genes Cancer* 2013; 4(1-2):54-60.

PTEN

1. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst*. Nov 6 2013;105(21):1607-1616.

Thrombophilia

1. Supanc V, Sonicki Z, Vukasovic I et al. The role of classic risk factors and prothrombotic factor gene mutations in ischemic stroke risk development in young and middle-aged individuals. *J Stroke Cerebrovasc Dis* 2014; 23(3):e171-6.

TP53

1. Wasserman JD, Novokmet A, Eichler-Jonsson C, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: A children's oncology group study. *J Clin Oncol.* 2015 Feb 20;33(6):602-9.